{"id":"alpha1-blocker","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"2-5","effect":"Palpitations"},{"rate":"1-2","effect":"Syncope"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs selectively block alpha-1 adrenergic receptors, which mediate vasoconstriction and smooth muscle contraction. By antagonizing these receptors, alpha-1 blockers reduce peripheral vascular resistance (lowering blood pressure) and relax smooth muscle in the prostate and bladder neck (improving urinary flow). This dual action makes them useful in both hypertension and benign prostatic hyperplasia.","oneSentence":"Alpha-1 blockers inhibit alpha-1 adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:25:22.418Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Benign prostatic hyperplasia with lower urinary tract symptoms"}]},"trialDetails":[{"nctId":"NCT05931276","phase":"PHASE3","title":"CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-22","conditions":"End-Stage Kidney Disease, End-Stage Renal Disease","enrollment":2540},{"nctId":"NCT06999135","phase":"NA","title":"Comparison of Silodosin and Tamsulosin for Medical Expulsive Therapy in Patients With Ureteral Stones","status":"COMPLETED","sponsor":"Fatima Jinnah Medical University","startDate":"2023-10-01","conditions":"Tamsulosin, Silodosin, Medical Expulsive Therapy","enrollment":200},{"nctId":"NCT06737016","phase":"PHASE3","title":"Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2024-11-01","conditions":"Posterior Urethral Valve","enrollment":50},{"nctId":"NCT06020963","phase":"NA","title":"Can Acupoint Low Intensity Shockwave Therapy Improve Bladder Voiding Efficiency","status":"RECRUITING","sponsor":"Taichung Armed Forces General Hospital","startDate":"2023-08-11","conditions":"Detrusor Underactivity","enrollment":100},{"nctId":"NCT06265415","phase":"NA","title":"Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2024-03-30","conditions":"Severe Preeclampsia","enrollment":60},{"nctId":"NCT04365257","phase":"PHASE2","title":"Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2020-05-13","conditions":"COVID-19","enrollment":5},{"nctId":"NCT05087940","phase":"","title":"Treatment of Resistant Hypertension: Cohort Study","status":"COMPLETED","sponsor":"Galenika AD Beograd","startDate":"2021-06-01","conditions":"Resistant Hypertension","enrollment":731},{"nctId":"NCT03894345","phase":"PHASE1","title":"Prazosin Use in Adults With Anxiety Disorders","status":"SUSPENDED","sponsor":"University of Manitoba","startDate":"2019-05-24","conditions":"Anxiety, Anxiety Disorders","enrollment":20},{"nctId":"NCT03719001","phase":"EARLY_PHASE1","title":"Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-10-23","conditions":"Vascular Diseases","enrollment":40},{"nctId":"NCT04557202","phase":"PHASE3","title":"Effect of Perioperative Selective alpha1-blockers in Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-09-01","conditions":"Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones","enrollment":120},{"nctId":"NCT01953432","phase":"PHASE2","title":"Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-04-01","conditions":"Cocaine Dependence","enrollment":43},{"nctId":"NCT01145183","phase":"PHASE2","title":"Pharmacogenetics of Doxazosin for Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2010-03","conditions":"Cocaine Dependence","enrollment":96},{"nctId":"NCT02431754","phase":"PHASE4","title":"A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-04","conditions":"Benign Prostatic Hyperplasia","enrollment":171},{"nctId":"NCT00687388","phase":"PHASE4","title":"The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia","status":"WITHDRAWN","sponsor":"Samsung Medical Center","startDate":"2008-05","conditions":"Benign Prostatic Hyperplasia","enrollment":""},{"nctId":"NCT00130156","phase":"PHASE4","title":"Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-10","conditions":"High Blood Pressure","enrollment":93},{"nctId":"NCT00151567","phase":"PHASE3","title":"Evaluation of Tamsulosin in the Treatment of Ureteral Stones","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2002-02","conditions":"Ureterolithiasis, Ureteral Calculi","enrollment":129},{"nctId":"NCT01431612","phase":"PHASE1, PHASE2","title":"Effects of Adrenergic Drugs on the Fluid Balance During Surgery","status":"COMPLETED","sponsor":"Sodertalje Hospital","startDate":"2008-11","conditions":"Ovarian Cyst","enrollment":60},{"nctId":"NCT00848081","phase":"PHASE3","title":"A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-03","conditions":"Benign Prostatic Hyperplasia","enrollment":318}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":214,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Alpha1 Blocker","genericName":"Alpha1 Blocker","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alpha-1 blockers inhibit alpha-1 adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction. Used for Hypertension, Benign prostatic hyperplasia with lower urinary tract symptoms.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}